The weight-loss drugs that kicked off America's GLP-1 craze are about to get a lot less expensive, though only certain customers will notice the savings. Novo Nordisk said it will slash list prices of ...

Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...

Novo's drug, CagriSema, didn't achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly's rival drug tirzepatide. The stock plummeted on Monday, hitting its ...

CagriSema shows 23% weight loss versus 25.5% for Zepbound Novo's shares drop 15% Lilly's shares rise 4% in US pre-market trading Outcome is 'worst-case scenario' for Novo, investor says Few analysts ...

Novo Nordisk (NYSE: NVO) hasn't been getting much love on Wall Street. The stock trades down 66% from its 2024 highs and just took a big hit after the company offered weak guidance for 2026. However, ...

Novo Nordisk's next diabetes/weight loss medicine should be better than its current crown jewel. The Danish drugmaker is still facing some challenges, but its pipeline could get it out of trouble. Can ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...

COPENHAGEN, Denmark — Novo Nordisk sued Hims and Hers Health on Monday over alleged patent infringement after the U.S. telehealth firm launched, then canceled, a $49 copy of Novo's weight-loss pill ...

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knockoffs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the ...

Hims & Hers (HIMS) on Monday called a patent lawsuit filed by Novo Nordisk (NVO) over IP rights linked to the Danish drugmaker’s weight loss therapy, semaglutide, “a blatant attack” targeting ...

Novo Nordisk, maker of Wegovy, saw its stock rise 6.5% after the opening bell on Monday. The company and the U.S. Food and Drug Administration threatened legal action against Hims & Hers, over its ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...